63rd HEIDELBERG GRAND ROUNDS

Liquid Biopsy

Chairs:
Prof. Dr. Andreas Trumpp
Prof. Dr. Stefan M. Pfister

March 12nd, 2019
16:00 – 18:00
DKFZ, Communication Center, Lecture Hall

Please register by 11th March at the latest.

For this event, two points for continuing education will be given by the Landesärztekammer.

For DKFZ PhD students, attendance of 5 Grand Rounds will be awarded with 1 credit point for the Blue Sheet. Please don't forget to collect the attendance slip.

Information and registration:
Fortbildungs- und Veranstaltungsorganisation des Nationalen Centrums für Tumorerkrankungen
Heidelberg School of Oncology

Im Neuenheimer Feld 460
69120 Heidelberg
Phone 06221 56-6558
Fax 06221 56-5094
hso@nct-heidelberg.de

www.nct-heidelberg.de/anmeldung

Marketing sponsored by:

Boehringer Ingelheim Pharma GmbH & Co. KG	*500,00 €*
Fresenius Kabi Deutschland GmbH	*1.000,00 €*
Janssen-Cilag GmbH	*1.500,00 €*
MSD Sharp & Dohme GmbH	*1.000,00 €*
Novartis Pharma GmbH	*1.000,00 €*
Roche Pharma AG	*500,00 €*

NCT
NATIONALES CENTRUM FÜR TUMORERKRANKUNGEN HEIDELBERG

getragen von:
Deutsches Krebsforschungszentrum
Universitätsklinikum Heidelberg
Thoraxklinik-Heidelberg
Deutsche Krebshilfe

Professor Caroline Dive, CBE, is internationally renowned for advancing circulating biomarker research, with a strong focus on circulating tumour cells (CTCs), particularly in lung cancer. She leads the Manchester Cancer Centre for Biomarker Sciences (over 100 staff) at the Cancer Research UK Manchester Institute, coordinating activities of scientists, bioinformaticians and clinicians. She has validated and implemented pharmacodynamic, prognostic and predictive biomarkers in clinical trials, working in tandem with clinical researchers and the Christie NHS Foundation Trust Cancer Treatment Centre. She developed unique xenotransplantation models using CTCs enriched from small cell lung cancer patients' blood samples, providing a fully tractable system for therapy testing and understanding drug resistance mechanisms, a landmark development in the field.

Professor Michael R. Speicher, is Professor of Human Genetics and Head of the Institute of Human Genetics at the Medical University of Graz in Austria. For many years Dr. Speicher studied chromosome structure and morphology using various molecular cytogenetic approaches. His current research is focused on hereditary tumor syndromes, the contribution of germline and somatic genomic variants to cancer, and liquid biopsies.

Professor Thomas Wuerdinger studied molecular biology in Amsterdam and received his PhD in Utrecht, focussing on oncolytic viruses. He spent 3 years as postdoctoral fellow at Harvard Medical School. Currently he is professor at the Cancer Center Amsterdam where he works on the preclinical developments of new therapies and diagnostics directed against brain cancer, with potential spin-off for other tumor types. To advance cancer diagnostics in the field of liquid biopsies he studied exosomes and platelets as carriers of RNA biomarkers, this has resulted in the formation of thromboDx BV and Exbiome BV.

Dr. Martin Sprick heads the group Experimental Oncology at the HI-STEM institute at the DKFZ. His research is focused on the discovery of drug-resistance mechanisms in cancer, identification of markers for patient stratification and fundamental mechanisms that determine cancer evolution and aggressiveness. He is active in the development of novel pre-clinical models for various cancer entities.

Prof. Dr. Caroline Dive University of Manchester	Keynote – Multiple Uses of Liquid Biopsy in Lung Cancer
Prof. Dr. Michael Speicher Medical University of Graz	Epigenetic and Nucleosome Footprint in cfDNA
Prof. Dr. Tom Würdinger Neurosurgical Center Amsterdam (NCA)	Diagnostic in Tumor Educated Platelets
Dr. Martin Sprick HI-STEM gGmbH, German Cancer Research Center Heidelberg	Single Cell Analysis and Expansion of Breast Cancer CTCs